Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
28 nov. 2022 06h00 HE
|
Helsinn Healthcare S.A.
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US
20 août 2020 09h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...
Helsinn announces launch of oral formulation of Akynzeo® in China
09 juin 2020 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States
02 juin 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron)
23 mars 2020 06h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...
Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019
13 déc. 2019 09h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, December 13, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
02 janv. 2019 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
12 déc. 2018 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
31 juil. 2018 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...